Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Boceprevir
- Accession Number
- DB08873 (DB05665)
- Type
- Small Molecule
- Groups
- Approved, Withdrawn
- Description
Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [7]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [Synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs [5]. Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. Despite this disadvantage Boceprevir is still effective against HCV when paired with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b.
In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b as first line therapy for Hepatitis C [5]. Boceprevir, Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b are used with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality [6].
Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C. Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b [FDA Label]. Victrelis is no longer widely used as interferon-free therapies have been developed.
- Structure
Structure for DB08873 (Boceprevir)
- Synonyms
- Not Available
- External IDs
- EBP 520 / EBP-520 / SCH 503034 / SCH-503034
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Victrelis Capsule 200 mg Oral Merck Sharp & Dohme Limited 2011-07-18 Not applicable EU 
Victrelis Capsule 200 mg Oral Merck Ltd. 2011-08-02 2017-01-10 Canada 
Victrelis Capsule 200 mg Oral Merck Sharp & Dohme Limited 2011-07-18 Not applicable EU Victrelis Capsule 200 mg/1 Oral Merck Sharp & Dohme Limited 2011-05-13 2017-11-16 US 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Victrelis Triple Boceprevir (200 mg) + Peginterferon alfa-2b (120 mcg) + Ribavirin (200 mg) Capsule; Powder, for solution Oral; Subcutaneous Merck Ltd. 2011-08-16 2016-09-02 Canada Victrelis Triple Boceprevir (200 mg) + Peginterferon alfa-2b (80 mcg) + Ribavirin (200 mg) Capsule; Powder, for solution Oral; Subcutaneous Merck Ltd. 2011-08-16 2017-01-10 Canada Victrelis Triple Boceprevir (200 mg) + Peginterferon alfa-2b (150 mcg) + Ribavirin (200 mg) Capsule; Powder, for solution Oral; Subcutaneous Merck Ltd. 2011-08-16 2016-09-02 Canada Victrelis Triple Boceprevir (200 mg) + Peginterferon alfa-2b (100 mcg) + Ribavirin (200 mg) Capsule; Powder, for solution Oral; Subcutaneous Merck Ltd. 2011-08-16 2017-01-10 Canada - Categories
- Acids, Acyclic
- Amino Acids
- Amino Acids, Cyclic
- Amino Acids, Peptides, and Proteins
- Antiinfectives for Systemic Use
- Antivirals for Systemic Use
- Combined Inhibitors of CYP3A4 and P-glycoprotein
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A Inhibitors (strong)
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (strong)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A5 Inhibitors (strong)
- Cytochrome P-450 CYP3A5 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Direct Acting Antivirals
- Hepatitis C Virus NS3/4A Protease Inhibitor
- Imines
- Imino Acids
- NS3/4A Protease Inhibitors
- P-glycoprotein/ABCB1 Inhibitors
- Protease Inhibitors
- UNII
- 89BT58KELH
- CAS number
- 394730-60-0
- Weight
- Average: 519.6767
Monoisotopic: 519.342069575 - Chemical Formula
- C27H45N5O5
- InChI Key
- LHHCSNFAOIFYRV-DOVBMPENSA-N
- InChI
- InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
- IUPAC Name
- 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide
- SMILES
- [H][[email protected]]12CN([[email protected]](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[[email protected]@]1([H])C2(C)C)C(=O)[[email protected]@H](NC(=O)NC(C)(C)C)C(C)(C)C
Pharmacology
- Indication
Boceprevir, when used in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b is indicated for use in the treatment of chronic HCV genotype 1 infection in adults [FDA Label].
- Structured Indications
- Pharmacodynamics
Boceprevir is classified as a direct-acting antiviral (DAA) and prevents viral replication in HCV genotype 1 [FDA Label].
- Mechanism of action
Boceprevir is a NS3/4a protease inhibitor used to inhibit viral HCV replication [FDA Label]. NS3/4a protease is an integral part of viral replication and mediates the cleavage the virally encoded polyprotein to mature proteins (NS4A, NS4B, NS5A and NS5B) [FDA Label]. Boceprevir covalently but reversibly binds the serine (S139) resiude in the active site via a (α)-ketoamide functional group. This inhibits the proteolytic acitvity of the HCV 1a and 1b encoded enzyme.
Target Actions Organism ANS3/4A protein inhibitorHepatitis C virus - Absorption
Boceprevir reaches peak plasma concentration 2 hours after administration [FDA Label]. Absolute bioavailability has not been determined. When taken with food exposure increases up to 65%. In capsule, Boceprevir consists of two diaseromers in a 1:1 ratio. In plasma this ratio changes to 2:1 favoring the active diastereomer.
- Volume of distribution
The mean apparent volume of distribution for Bocepravir is 772 litres at steady state [FDA Label].
- Protein binding
Bocepravir is approximately 75% bound to human plasma proteins following a single dose [FDA Label].
- Metabolism
Bocepravir is primarily metabolized via the aldo-ketoreductase-mediated pathway producing a diastereomeric mix of metabolites at a 4 fold greater exposure than the parent compound [FDA Label]. Boceprevir also undergoes oxidative metabolism via CYP3A4/5, although to a lesser extent.
- Route of elimination
Boceprevir is mainly eliminated in the feces (79%) with a small amount eliminated in the urine (9%) [FDA Label]. Approximately 8% and 3% is excreted as the parent compound in the feces and urine respectively.
- Half life
Boceprevir has a mean half-life of elimination of 3.4 hours [FDA Label].
- Clearance
Boceprevir has a mean total body clearance of 161 liters per hour [FDA Label].
- Toxicity
The most commonly reported adverse reactions in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when Boceprevir was used in combination with Ribavirin and Peginterferon alfa-2a/Peginterferon alfa-2b [FDA Label].
- Affected organisms
- Hepatitis C Virus
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 1,10-Phenanthroline The serum concentration of 1,10-Phenanthroline can be decreased when it is combined with Boceprevir. Experimental 16-Bromoepiandrosterone The serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Boceprevir. Investigational 19-norandrostenedione The serum concentration of 19-norandrostenedione can be increased when it is combined with Boceprevir. Experimental, Illicit 3,4-Dichloroisocoumarin The serum concentration of 3,4-Dichloroisocoumarin can be decreased when it is combined with Boceprevir. Experimental 4-(2-Aminoethyl)Benzenesulfonyl Fluoride The serum concentration of 4-(2-Aminoethyl)Benzenesulfonyl Fluoride can be decreased when it is combined with Boceprevir. Experimental 5-androstenedione The serum concentration of 5-androstenedione can be increased when it is combined with Boceprevir. Experimental, Illicit Abacavir The serum concentration of Abacavir can be decreased when it is combined with Boceprevir. Approved, Investigational Abemaciclib The risk or severity of adverse effects can be increased when Boceprevir is combined with Abemaciclib. Approved, Investigational Abiraterone The metabolism of Abiraterone can be decreased when combined with Boceprevir. Approved Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Boceprevir. Approved, Investigational Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Boceprevir. Approved Adinazolam The metabolism of Adinazolam can be decreased when combined with Boceprevir. Approved Afatinib The serum concentration of Afatinib can be increased when it is combined with Boceprevir. Approved Albendazole The metabolism of Albendazole can be decreased when combined with Boceprevir. Approved, Vet Approved Alclometasone The metabolism of Alclometasone can be decreased when combined with Boceprevir. Approved Aldosterone The serum concentration of Aldosterone can be increased when it is combined with Boceprevir. Experimental, Investigational Alfentanil The metabolism of Alfentanil can be decreased when combined with Boceprevir. Approved, Illicit Alfuzosin The serum concentration of Alfuzosin can be increased when it is combined with Boceprevir. Approved, Investigational Aliskiren The metabolism of Aliskiren can be decreased when combined with Boceprevir. Approved, Investigational Allylestrenol The metabolism of Allylestrenol can be decreased when combined with Boceprevir. Approved Almotriptan The serum concentration of Almotriptan can be increased when it is combined with Boceprevir. Approved, Investigational Alogliptin The serum concentration of Alogliptin can be decreased when it is combined with Boceprevir. Approved Alosetron The serum concentration of Alosetron can be increased when it is combined with Boceprevir. Approved, Withdrawn Alpha-1-proteinase inhibitor The serum concentration of Alpha-1-proteinase inhibitor can be decreased when it is combined with Boceprevir. Approved alpha-Tocopherol acetate The metabolism of alpha-Tocopherol acetate can be decreased when combined with Boceprevir. Approved Alprazolam The serum concentration of Alprazolam can be increased when it is combined with Boceprevir. Approved, Illicit, Investigational Ambrisentan The metabolism of Ambrisentan can be decreased when combined with Boceprevir. Approved, Investigational Ambroxol The metabolism of Ambroxol can be decreased when combined with Boceprevir. Approved, Investigational Ambroxol acefyllinate The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Boceprevir. Experimental, Investigational Amcinonide The serum concentration of Amcinonide can be increased when it is combined with Boceprevir. Approved Amineptine The serum concentration of Amineptine can be increased when it is combined with Boceprevir. Illicit, Withdrawn Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Boceprevir. Approved, Withdrawn Aminophylline The metabolism of Aminophylline can be decreased when combined with Boceprevir. Approved Amiodarone The serum concentration of Amiodarone can be increased when it is combined with Boceprevir. Approved, Investigational Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Boceprevir. Approved Amlodipine The metabolism of Amlodipine can be decreased when combined with Boceprevir. Approved Amoxapine The serum concentration of Amoxapine can be increased when it is combined with Boceprevir. Approved Amprenavir The serum concentration of Amprenavir can be decreased when it is combined with Boceprevir. Approved, Investigational Androstenedione The serum concentration of Androstenedione can be increased when it is combined with Boceprevir. Experimental, Illicit Anecortave The serum concentration of Anecortave can be increased when it is combined with Boceprevir. Investigational anecortave acetate The serum concentration of anecortave acetate can be increased when it is combined with Boceprevir. Investigational Antipyrine The metabolism of Antipyrine can be decreased when combined with Boceprevir. Approved, Investigational Antithrombin III human The serum concentration of Antithrombin III human can be decreased when it is combined with Boceprevir. Approved Apalutamide The serum concentration of Boceprevir can be decreased when it is combined with Apalutamide. Approved, Investigational Apixaban The serum concentration of Apixaban can be decreased when it is combined with Boceprevir. Approved Apremilast The metabolism of Apremilast can be decreased when combined with Boceprevir. Approved, Investigational Aprepitant The serum concentration of Boceprevir can be increased when it is combined with Aprepitant. Approved, Investigational Aprotinin The serum concentration of Aprotinin can be decreased when it is combined with Boceprevir. Approved, Investigational, Withdrawn Argatroban The serum concentration of Argatroban can be decreased when it is combined with Boceprevir. Approved, Investigational Aripiprazole The serum concentration of Aripiprazole can be increased when it is combined with Boceprevir. Approved, Investigational Artemether The metabolism of Artemether can be decreased when combined with Boceprevir. Approved Asenapine The metabolism of Asenapine can be decreased when combined with Boceprevir. Approved Astemizole The serum concentration of Astemizole can be increased when it is combined with Boceprevir. Approved, Withdrawn Asunaprevir The serum concentration of Asunaprevir can be decreased when it is combined with Boceprevir. Approved, Investigational, Withdrawn Atamestane The serum concentration of Atamestane can be increased when it is combined with Boceprevir. Investigational Atazanavir The serum concentration of Atazanavir can be decreased when it is combined with Boceprevir. Approved, Investigational Atomoxetine The metabolism of Boceprevir can be decreased when combined with Atomoxetine. Approved Atorvastatin The serum concentration of Atorvastatin can be increased when it is combined with Boceprevir. Approved Avanafil The serum concentration of Avanafil can be increased when it is combined with Boceprevir. Approved Axitinib The serum concentration of Axitinib can be increased when it is combined with Boceprevir. Approved, Investigational Azelastine The metabolism of Azelastine can be decreased when combined with Boceprevir. Approved Azithromycin The metabolism of Azithromycin can be decreased when combined with Boceprevir. Approved Banoxantrone The metabolism of Banoxantrone can be decreased when combined with Boceprevir. Investigational Baricitinib The metabolism of Baricitinib can be decreased when combined with Boceprevir. Approved, Investigational Barnidipine The serum concentration of Barnidipine can be increased when it is combined with Boceprevir. Approved Batimastat The serum concentration of Batimastat can be decreased when it is combined with Boceprevir. Experimental Beclomethasone dipropionate The serum concentration of Beclomethasone dipropionate can be increased when it is combined with Boceprevir. Approved, Investigational Bedaquiline The serum concentration of Bedaquiline can be increased when it is combined with Boceprevir. Approved Benazepril The serum concentration of Benazepril can be decreased when it is combined with Boceprevir. Approved, Investigational Benidipine The metabolism of Benidipine can be decreased when combined with Boceprevir. Approved, Investigational Benzamidine The serum concentration of Benzamidine can be decreased when it is combined with Boceprevir. Experimental Benzphetamine The metabolism of Benzphetamine can be decreased when combined with Boceprevir. Approved, Illicit Benzyl alcohol The metabolism of Benzyl alcohol can be decreased when combined with Boceprevir. Approved Bepridil The serum concentration of Bepridil can be increased when it is combined with Boceprevir. Approved, Withdrawn Betamethasone The serum concentration of Betamethasone can be increased when it is combined with Boceprevir. Approved, Vet Approved Bexarotene The metabolism of Bexarotene can be decreased when combined with Boceprevir. Approved, Investigational Bezafibrate The metabolism of Bezafibrate can be decreased when combined with Boceprevir. Approved, Investigational Bicalutamide The metabolism of Bicalutamide can be decreased when combined with Boceprevir. Approved Bictegravir The metabolism of Bictegravir can be decreased when combined with Boceprevir. Approved, Investigational Bisoprolol The metabolism of Bisoprolol can be decreased when combined with Boceprevir. Approved Bivalirudin The serum concentration of Bivalirudin can be decreased when it is combined with Boceprevir. Approved, Investigational Blonanserin The metabolism of Blonanserin can be decreased when combined with Boceprevir. Approved, Investigational Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Boceprevir. Approved, Investigational Bosentan The serum concentration of Boceprevir can be decreased when it is combined with Bosentan. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Boceprevir. Approved Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Boceprevir. Approved, Investigational Brexpiprazole The serum concentration of Brexpiprazole can be increased when it is combined with Boceprevir. Approved, Investigational Brigatinib The serum concentration of Brigatinib can be increased when it is combined with Boceprevir. Approved, Investigational Brinzolamide The serum concentration of Brinzolamide can be increased when it is combined with Boceprevir. Approved Brivaracetam The metabolism of Brivaracetam can be decreased when combined with Boceprevir. Approved, Investigational Bromazepam The metabolism of Bromazepam can be decreased when combined with Boceprevir. Approved, Illicit, Investigational Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Boceprevir. Approved, Investigational Brompheniramine The metabolism of Brompheniramine can be decreased when combined with Boceprevir. Approved Budesonide The serum concentration of Budesonide can be increased when it is combined with Boceprevir. Approved Bupivacaine The metabolism of Bupivacaine can be decreased when combined with Boceprevir. Approved, Investigational Buprenorphine The serum concentration of Buprenorphine can be decreased when it is combined with Boceprevir. Approved, Illicit, Investigational, Vet Approved Bupropion The metabolism of Bupropion can be decreased when combined with Boceprevir. Approved Buspirone The metabolism of Buspirone can be decreased when combined with Boceprevir. Approved, Investigational Busulfan The metabolism of Busulfan can be decreased when combined with Boceprevir. Approved, Investigational Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Boceprevir. Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Boceprevir. Approved Cabozantinib The serum concentration of Cabozantinib can be increased when it is combined with Boceprevir. Approved, Investigational Caffeine The metabolism of Caffeine can be decreased when combined with Boceprevir. Approved Calcitriol The metabolism of Calcitriol can be decreased when combined with Boceprevir. Approved, Nutraceutical Camostat The serum concentration of Camostat can be decreased when it is combined with Boceprevir. Experimental Canagliflozin The metabolism of Canagliflozin can be decreased when combined with Boceprevir. Approved Candoxatril The serum concentration of Candoxatril can be decreased when it is combined with Boceprevir. Experimental Candoxatrilat The serum concentration of Candoxatrilat can be decreased when it is combined with Boceprevir. Experimental Cannabidiol The metabolism of Cannabidiol can be decreased when combined with Boceprevir. Approved, Investigational Captopril The serum concentration of Captopril can be decreased when it is combined with Boceprevir. Approved Carbamazepine The serum concentration of Boceprevir can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbinoxamine The metabolism of Carbinoxamine can be decreased when combined with Boceprevir. Approved Cariprazine The metabolism of Cariprazine can be decreased when combined with Boceprevir. Approved, Investigational Carvedilol The metabolism of Carvedilol can be decreased when combined with Boceprevir. Approved, Investigational Celecoxib The metabolism of Celecoxib can be decreased when combined with Boceprevir. Approved, Investigational Celiprolol The metabolism of Celiprolol can be decreased when combined with Boceprevir. Approved, Investigational Cephalexin The metabolism of Cephalexin can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Boceprevir. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Boceprevir. Approved, Withdrawn Cevimeline The metabolism of Cevimeline can be decreased when combined with Boceprevir. Approved Chenodeoxycholic acid The metabolism of Chenodeoxycholic acid can be decreased when combined with Boceprevir. Approved Chlordiazepoxide The metabolism of Chlordiazepoxide can be decreased when combined with Boceprevir. Approved, Illicit, Investigational Chloroquine The metabolism of Chloroquine can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Chlorotrianisene The serum concentration of Chlorotrianisene can be decreased when it is combined with Boceprevir. Investigational, Withdrawn Chlorphenamine The metabolism of Chlorphenamine can be decreased when combined with Boceprevir. Approved Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Boceprevir. Approved Cholecalciferol The metabolism of Cholecalciferol can be decreased when combined with Boceprevir. Approved, Nutraceutical Cholesterol The serum concentration of Cholesterol can be decreased when it is combined with Boceprevir. Approved, Experimental, Investigational Chymostatin The serum concentration of Chymostatin can be decreased when it is combined with Boceprevir. Experimental Ciclesonide The metabolism of Ciclesonide can be decreased when combined with Boceprevir. Approved, Investigational Cilastatin The serum concentration of Cilastatin can be decreased when it is combined with Boceprevir. Approved, Investigational Cilazapril The serum concentration of Cilazapril can be decreased when it is combined with Boceprevir. Approved Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Boceprevir. Approved, Investigational Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Boceprevir. Approved Cisapride The serum concentration of Cisapride can be increased when it is combined with Boceprevir. Approved, Investigational, Withdrawn Citalopram The metabolism of Citalopram can be decreased when combined with Boceprevir. Approved Clarithromycin The serum concentration of Boceprevir can be increased when it is combined with Clarithromycin. Approved Clemastine The metabolism of Boceprevir can be decreased when combined with Clemastine. Approved, Investigational Clindamycin The metabolism of Clindamycin can be decreased when combined with Boceprevir. Approved, Vet Approved Clobazam The metabolism of Clobazam can be decreased when combined with Boceprevir. Approved, Illicit Clobetasol The serum concentration of Clobetasol can be increased when it is combined with Boceprevir. Approved, Investigational Clobetasol propionate The serum concentration of Clobetasol propionate can be increased when it is combined with Boceprevir. Approved Clobetasone The serum concentration of Clobetasone can be increased when it is combined with Boceprevir. Approved Clocortolone The serum concentration of Clocortolone can be increased when it is combined with Boceprevir. Approved Clofazimine The metabolism of Clofazimine can be decreased when combined with Boceprevir. Approved, Investigational Clofibrate The metabolism of Clofibrate can be decreased when combined with Boceprevir. Approved, Investigational clomethiazole The metabolism of clomethiazole can be decreased when combined with Boceprevir. Investigational Clomipramine The metabolism of Clomipramine can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Clonazepam The metabolism of Clonazepam can be decreased when combined with Boceprevir. Approved, Illicit Clonidine The metabolism of Clonidine can be decreased when combined with Boceprevir. Approved Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Boceprevir. Approved Clorazepate The metabolism of Clorazepate can be decreased when combined with Boceprevir. Approved, Illicit Clotiazepam The metabolism of Clotiazepam can be decreased when combined with Boceprevir. Approved, Illicit Clotrimazole The metabolism of Boceprevir can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The metabolism of Clozapine can be decreased when combined with Boceprevir. Approved Cobicistat The serum concentration of Boceprevir can be increased when it is combined with Cobicistat. Approved Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Boceprevir. Approved, Investigational Cocaine The metabolism of Cocaine can be decreased when combined with Boceprevir. Approved, Illicit Codeine The metabolism of Codeine can be decreased when combined with Boceprevir. Approved, Illicit Colchicine The serum concentration of Colchicine can be increased when it is combined with Boceprevir. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Boceprevir. Approved, Investigational Conjugated estrogens The serum concentration of Conjugated estrogens can be decreased when it is combined with Boceprevir. Approved Copanlisib The metabolism of Copanlisib can be decreased when combined with Boceprevir. Approved, Investigational Cortexolone 17α-propionate The serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Boceprevir. Investigational Corticosterone The serum concentration of Corticosterone can be increased when it is combined with Boceprevir. Experimental Cortisone acetate The metabolism of Cortisone acetate can be decreased when combined with Boceprevir. Approved, Investigational Crizotinib The serum concentration of Crizotinib can be increased when it is combined with Boceprevir. Approved Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Boceprevir. Approved Cyclophosphamide The risk or severity of adverse effects can be increased when Boceprevir is combined with Cyclophosphamide. Approved, Investigational Cyclosporine The serum concentration of Boceprevir can be increased when it is combined with Cyclosporine. Approved, Investigational, Vet Approved Cytarabine The metabolism of Cytarabine can be decreased when combined with Boceprevir. Approved, Investigational Dabigatran etexilate The serum concentration of Dabigatran etexilate can be decreased when it is combined with Boceprevir. Approved Dabrafenib The serum concentration of Boceprevir can be decreased when it is combined with Dabrafenib. Approved, Investigational Daclatasvir The serum concentration of Daclatasvir can be increased when it is combined with Boceprevir. Approved, Investigational Dantrolene The metabolism of Dantrolene can be decreased when combined with Boceprevir. Approved, Investigational Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Boceprevir. Approved Dapoxetine The serum concentration of Dapoxetine can be increased when it is combined with Boceprevir. Investigational Dapsone The metabolism of Dapsone can be decreased when combined with Boceprevir. Approved, Investigational Darexaban The serum concentration of Darexaban can be decreased when it is combined with Boceprevir. Investigational Darifenacin The metabolism of Darifenacin can be decreased when combined with Boceprevir. Approved, Investigational Darunavir The serum concentration of Darunavir can be decreased when it is combined with Boceprevir. Approved Dasabuvir The metabolism of Dasabuvir can be decreased when combined with Boceprevir. Approved Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Boceprevir. Approved, Investigational Daunorubicin The metabolism of Daunorubicin can be decreased when combined with Boceprevir. Approved Deferasirox The serum concentration of Boceprevir can be decreased when it is combined with Deferasirox. Approved, Investigational Deflazacort The metabolism of Deflazacort can be decreased when combined with Boceprevir. Approved, Investigational Delamanid Boceprevir may increase the QTc-prolonging activities of Delamanid. Approved, Investigational Delanzomib The serum concentration of Delanzomib can be decreased when it is combined with Boceprevir. Investigational Delapril The serum concentration of Delapril can be decreased when it is combined with Boceprevir. Experimental Delavirdine The serum concentration of Delavirdine can be decreased when it is combined with Boceprevir. Approved Desipramine The serum concentration of Desipramine can be increased when it is combined with Boceprevir. Approved, Investigational Desogestrel The serum concentration of Desogestrel can be increased when it is combined with Boceprevir. Approved Desonide The serum concentration of Desonide can be increased when it is combined with Boceprevir. Approved, Investigational Desoximetasone The serum concentration of Desoximetasone can be increased when it is combined with Boceprevir. Approved Desoxycorticosterone acetate The serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Boceprevir. Approved Desoxycorticosterone Pivalate The serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Boceprevir. Experimental, Vet Approved Desvenlafaxine The metabolism of Desvenlafaxine can be decreased when combined with Boceprevir. Approved, Investigational Deutetrabenazine The metabolism of Deutetrabenazine can be decreased when combined with Boceprevir. Approved, Investigational Dexamethasone The metabolism of Dexamethasone can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Boceprevir. Vet Approved Dexchlorpheniramine maleate The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Boceprevir. Approved Dexlansoprazole The metabolism of Dexlansoprazole can be decreased when combined with Boceprevir. Approved, Investigational Dextromethorphan The metabolism of Dextromethorphan can be decreased when combined with Boceprevir. Approved Dextropropoxyphene The metabolism of Dextropropoxyphene can be decreased when combined with Boceprevir. Approved, Illicit, Investigational, Withdrawn Diazepam The metabolism of Diazepam can be decreased when combined with Boceprevir. Approved, Illicit, Investigational, Vet Approved Dibenzepin The serum concentration of Dibenzepin can be increased when it is combined with Boceprevir. Experimental Diclofenac The metabolism of Diclofenac can be decreased when combined with Boceprevir. Approved, Vet Approved Dienestrol The serum concentration of Dienestrol can be decreased when it is combined with Boceprevir. Approved, Investigational Dienogest The serum concentration of Dienogest can be increased when it is combined with Boceprevir. Approved Diethylstilbestrol The serum concentration of Diethylstilbestrol can be decreased when it is combined with Boceprevir. Approved, Investigational Diflorasone The serum concentration of Diflorasone can be increased when it is combined with Boceprevir. Approved Difluocortolone The serum concentration of Difluocortolone can be increased when it is combined with Boceprevir. Approved, Investigational, Withdrawn Difluprednate The serum concentration of Difluprednate can be increased when it is combined with Boceprevir. Approved Digitoxin The metabolism of Digitoxin can be decreased when combined with Boceprevir. Approved, Investigational Digoxin The serum concentration of Digoxin can be increased when it is combined with Boceprevir. Approved Dihydrocodeine The metabolism of Dihydrocodeine can be decreased when combined with Boceprevir. Approved, Illicit Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Boceprevir. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Boceprevir. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Boceprevir. Experimental Dihydroergotamine The serum concentration of Dihydroergotamine can be increased when it is combined with Boceprevir. Approved, Investigational Diltiazem The metabolism of Diltiazem can be decreased when combined with Boceprevir. Approved, Investigational Disopyramide The metabolism of Disopyramide can be decreased when combined with Boceprevir. Approved Disulfiram The metabolism of Disulfiram can be decreased when combined with Boceprevir. Approved Docetaxel The metabolism of Docetaxel can be decreased when combined with Boceprevir. Approved, Investigational Dofetilide The serum concentration of Dofetilide can be increased when it is combined with Boceprevir. Approved, Investigational Dolasetron The metabolism of Dolasetron can be decreased when combined with Boceprevir. Approved, Investigational Domperidone The serum concentration of Domperidone can be increased when it is combined with Boceprevir. Approved, Investigational, Vet Approved Donepezil The metabolism of Donepezil can be decreased when combined with Boceprevir. Approved Dorzolamide The metabolism of Dorzolamide can be decreased when combined with Boceprevir. Approved Dosulepin The serum concentration of Dosulepin can be increased when it is combined with Boceprevir. Approved Doxazosin The serum concentration of Doxazosin can be increased when it is combined with Boceprevir. Approved Doxepin The metabolism of Doxepin can be decreased when combined with Boceprevir. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Boceprevir. Approved, Investigational Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Boceprevir. Approved, Investigational Doxycycline The metabolism of Boceprevir can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Boceprevir. Approved, Illicit Dronedarone The serum concentration of Dronedarone can be increased when it is combined with Boceprevir. Approved Drospirenone The serum concentration of Drospirenone can be increased when it is combined with Boceprevir. Approved Dutasteride The serum concentration of Dutasteride can be increased when it is combined with Boceprevir. Approved, Investigational Dyphylline The serum concentration of Dyphylline can be decreased when it is combined with Boceprevir. Approved Ecabet The serum concentration of Ecabet can be decreased when it is combined with Boceprevir. Approved, Investigational Edoxaban The serum concentration of Edoxaban can be decreased when it is combined with Boceprevir. Approved Efavirenz The serum concentration of Boceprevir can be decreased when it is combined with Efavirenz. Approved, Investigational Elafin The serum concentration of Elafin can be decreased when it is combined with Boceprevir. Investigational Elbasvir The metabolism of Elbasvir can be decreased when combined with Boceprevir. Approved Eletriptan The metabolism of Eletriptan can be decreased when combined with Boceprevir. Approved, Investigational Eliglustat The serum concentration of Eliglustat can be increased when it is combined with Boceprevir. Approved Elvitegravir The metabolism of Elvitegravir can be decreased when combined with Boceprevir. Approved Enalapril The serum concentration of Enalapril can be decreased when it is combined with Boceprevir. Approved, Vet Approved Enalaprilat The serum concentration of Enalaprilat can be decreased when it is combined with Boceprevir. Approved Enalkiren The serum concentration of Enalkiren can be decreased when it is combined with Boceprevir. Experimental Enasidenib The metabolism of Enasidenib can be decreased when combined with Boceprevir. Approved, Investigational Enfuvirtide The serum concentration of Enfuvirtide can be increased when it is combined with Boceprevir. Approved, Investigational Enzalutamide The serum concentration of Boceprevir can be decreased when it is combined with Enzalutamide. Approved Epigallocatechin Gallate The serum concentration of Epigallocatechin Gallate can be decreased when it is combined with Boceprevir. Investigational Epinastine The metabolism of Epinastine can be decreased when combined with Boceprevir. Approved, Investigational Eplerenone The serum concentration of Eplerenone can be increased when it is combined with Boceprevir. Approved Equilenin The serum concentration of Equilenin can be increased when it is combined with Boceprevir. Experimental Equilin The serum concentration of Equilin can be increased when it is combined with Boceprevir. Approved Ergocalciferol The metabolism of Ergocalciferol can be decreased when combined with Boceprevir. Approved, Nutraceutical Ergoloid mesylate The serum concentration of Ergoloid mesylate can be increased when it is combined with Boceprevir. Approved Ergonovine The serum concentration of Ergonovine can be increased when it is combined with Boceprevir. Approved Ergotamine The serum concentration of Ergotamine can be increased when it is combined with Boceprevir. Approved Erlotinib The serum concentration of Erlotinib can be increased when it is combined with Boceprevir. Approved, Investigational Erythromycin The metabolism of Erythromycin can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Escitalopram The serum concentration of Escitalopram can be decreased when it is combined with Boceprevir. Approved, Investigational Esmirtazapine The serum concentration of Esmirtazapine can be increased when it is combined with Boceprevir. Investigational Esomeprazole The metabolism of Esomeprazole can be decreased when combined with Boceprevir. Approved, Investigational Estazolam The serum concentration of Estazolam can be increased when it is combined with Boceprevir. Approved, Illicit Estradiol The serum concentration of Estradiol can be decreased when it is combined with Boceprevir. Approved, Investigational, Vet Approved Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Estramustine The serum concentration of Estramustine can be decreased when it is combined with Boceprevir. Approved, Investigational Estrogens, esterified The serum concentration of Estrogens, esterified can be decreased when it is combined with Boceprevir. Approved Estrone The metabolism of Estrone can be decreased when combined with Boceprevir. Approved Estrone sulfate The serum concentration of Estrone sulfate can be decreased when it is combined with Boceprevir. Approved Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Boceprevir. Approved, Investigational Ethanol The metabolism of Ethanol can be decreased when combined with Boceprevir. Approved Ethinyl Estradiol The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Boceprevir. Approved Ethosuximide The metabolism of Ethosuximide can be decreased when combined with Boceprevir. Approved Ethylmorphine The metabolism of Ethylmorphine can be decreased when combined with Boceprevir. Approved, Illicit Ethynodiol diacetate The serum concentration of Ethynodiol diacetate can be increased when it is combined with Boceprevir. Approved Etizolam The serum concentration of Etizolam can be increased when it is combined with Boceprevir. Approved Etonogestrel The serum concentration of Etonogestrel can be increased when it is combined with Boceprevir. Approved, Investigational Etoposide The metabolism of Etoposide can be decreased when combined with Boceprevir. Approved Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Boceprevir. Approved, Investigational Etravirine The serum concentration of Etravirine can be decreased when it is combined with Boceprevir. Approved Everolimus The serum concentration of Everolimus can be increased when it is combined with Boceprevir. Approved Exemestane The metabolism of Exemestane can be decreased when combined with Boceprevir. Approved, Investigational Faldaprevir The serum concentration of Faldaprevir can be decreased when it is combined with Boceprevir. Investigational Famciclovir The metabolism of Famciclovir can be decreased when combined with Boceprevir. Approved, Investigational Felbamate The metabolism of Felbamate can be decreased when combined with Boceprevir. Approved Felodipine The metabolism of Felodipine can be decreased when combined with Boceprevir. Approved, Investigational Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Boceprevir. Approved Fentanyl The serum concentration of Fentanyl can be increased when it is combined with Boceprevir. Approved, Illicit, Investigational, Vet Approved Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Boceprevir. Approved Finasteride The metabolism of Finasteride can be decreased when combined with Boceprevir. Approved Fingolimod The metabolism of Fingolimod can be decreased when combined with Boceprevir. Approved, Investigational Flecainide The serum concentration of Flecainide can be increased when it is combined with Boceprevir. Approved, Withdrawn Flibanserin The serum concentration of Flibanserin can be increased when it is combined with Boceprevir. Approved, Investigational Fluasterone The serum concentration of Fluasterone can be increased when it is combined with Boceprevir. Investigational Fluconazole The metabolism of Boceprevir can be decreased when combined with Fluconazole. Approved, Investigational Fludrocortisone The serum concentration of Fludrocortisone can be increased when it is combined with Boceprevir. Approved, Investigational Flumethasone The serum concentration of Flumethasone can be increased when it is combined with Boceprevir. Approved, Vet Approved Flunisolide The metabolism of Flunisolide can be decreased when combined with Boceprevir. Approved, Investigational Flunitrazepam The metabolism of Flunitrazepam can be decreased when combined with Boceprevir. Approved, Illicit Fluocinolone Acetonide The serum concentration of Fluocinolone Acetonide can be increased when it is combined with Boceprevir. Approved, Investigational, Vet Approved Fluocinonide The serum concentration of Fluocinonide can be increased when it is combined with Boceprevir. Approved, Investigational Fluocortolone The serum concentration of Fluocortolone can be increased when it is combined with Boceprevir. Approved, Withdrawn Fluorometholone The metabolism of Fluorometholone can be decreased when combined with Boceprevir. Approved, Investigational Fluoxetine The metabolism of Fluoxetine can be decreased when combined with Boceprevir. Approved, Vet Approved Fluprednidene The serum concentration of Fluprednidene can be increased when it is combined with Boceprevir. Approved, Withdrawn Fluprednisolone The serum concentration of Fluprednisolone can be increased when it is combined with Boceprevir. Approved Flurandrenolide The serum concentration of Flurandrenolide can be increased when it is combined with Boceprevir. Approved Flurazepam The metabolism of Flurazepam can be decreased when combined with Boceprevir. Approved, Illicit, Investigational Flutamide The metabolism of Flutamide can be decreased when combined with Boceprevir. Approved, Investigational Fluticasone furoate The metabolism of Fluticasone furoate can be decreased when combined with Boceprevir. Approved Fluticasone propionate The serum concentration of Fluticasone propionate can be increased when it is combined with Boceprevir. Approved Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Boceprevir. Approved Fluvoxamine The metabolism of Boceprevir can be decreased when combined with Fluvoxamine. Approved, Investigational Formestane The serum concentration of Formestane can be increased when it is combined with Boceprevir. Approved, Investigational, Withdrawn Fosamprenavir The serum concentration of Fosamprenavir can be decreased when it is combined with Boceprevir. Approved Fosaprepitant The serum concentration of Boceprevir can be increased when it is combined with Fosaprepitant. Approved Fosinopril The serum concentration of Fosinopril can be decreased when it is combined with Boceprevir. Approved Fosphenytoin The serum concentration of Boceprevir can be decreased when it is combined with Fosphenytoin. Approved, Investigational Fulvestrant The metabolism of Fulvestrant can be decreased when combined with Boceprevir. Approved, Investigational Fusidic Acid The serum concentration of Boceprevir can be increased when it is combined with Fusidic Acid. Approved, Investigational Gabexate The serum concentration of Gabexate can be decreased when it is combined with Boceprevir. Investigational Galantamine The metabolism of Galantamine can be decreased when combined with Boceprevir. Approved Garlic The serum concentration of Boceprevir can be decreased when it is combined with Garlic. Approved Gefitinib The metabolism of Gefitinib can be decreased when combined with Boceprevir. Approved, Investigational Geldanamycin The serum concentration of Geldanamycin can be decreased when it is combined with Boceprevir. Experimental, Investigational Gemfibrozil The metabolism of Gemfibrozil can be decreased when combined with Boceprevir. Approved Gestodene The serum concentration of Gestodene can be increased when it is combined with Boceprevir. Approved, Investigational Glipizide The metabolism of Glipizide can be decreased when combined with Boceprevir. Approved, Investigational Glyburide The metabolism of Glyburide can be decreased when combined with Boceprevir. Approved GM6001 The serum concentration of GM6001 can be decreased when it is combined with Boceprevir. Experimental Granisetron The metabolism of Granisetron can be decreased when combined with Boceprevir. Approved, Investigational Grazoprevir The metabolism of Grazoprevir can be decreased when combined with Boceprevir. Approved Grepafloxacin The metabolism of Grepafloxacin can be decreased when combined with Boceprevir. Approved, Investigational, Withdrawn Guanfacine The serum concentration of Guanfacine can be increased when it is combined with Boceprevir. Approved, Investigational Halcinonide The serum concentration of Halcinonide can be increased when it is combined with Boceprevir. Approved, Investigational, Withdrawn Halofantrine The serum concentration of Halofantrine can be increased when it is combined with Boceprevir. Approved Haloperidol The metabolism of Haloperidol can be decreased when combined with Boceprevir. Approved Halothane The metabolism of Halothane can be decreased when combined with Boceprevir. Approved, Vet Approved HE3286 The serum concentration of HE3286 can be increased when it is combined with Boceprevir. Investigational Hexestrol The serum concentration of Hexestrol can be decreased when it is combined with Boceprevir. Withdrawn Hexobarbital The metabolism of Hexobarbital can be decreased when combined with Boceprevir. Approved Histamine The metabolism of Histamine can be decreased when combined with Boceprevir. Approved, Investigational Hydrocodone The serum concentration of Hydrocodone can be increased when it is combined with Boceprevir. Approved, Illicit Hydrocortisone The metabolism of Hydrocortisone can be decreased when combined with Boceprevir. Approved, Vet Approved Hydromorphone The metabolism of Hydromorphone can be decreased when combined with Boceprevir. Approved, Illicit Hydroxyprogesterone caproate The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Boceprevir. Approved, Investigational Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Boceprevir. Approved Icotinib The metabolism of Icotinib can be decreased when combined with Boceprevir. Approved, Investigational Idelalisib The serum concentration of Idelalisib can be increased when it is combined with Boceprevir. Approved Idraparinux The serum concentration of Idraparinux can be decreased when it is combined with Boceprevir. Investigational Ifosfamide The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Boceprevir resulting in a loss in efficacy. Approved Iloperidone The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Boceprevir. Approved Imatinib The serum concentration of Imatinib can be increased when it is combined with Boceprevir. Approved Imidafenacin The serum concentration of Imidafenacin can be increased when it is combined with Boceprevir. Approved, Investigational Imidapril The serum concentration of Imidapril can be decreased when it is combined with Boceprevir. Investigational Imipramine The metabolism of Imipramine can be decreased when combined with Boceprevir. Approved Imiquimod The metabolism of Imiquimod can be decreased when combined with Boceprevir. Approved, Investigational Indacaterol The metabolism of Indacaterol can be decreased when combined with Boceprevir. Approved Indapamide The metabolism of Indapamide can be decreased when combined with Boceprevir. Approved Indinavir The serum concentration of Indinavir can be decreased when it is combined with Boceprevir. Approved Ipratropium bromide The metabolism of Ipratropium bromide can be decreased when combined with Boceprevir. Approved Iprindole The serum concentration of Iprindole can be increased when it is combined with Boceprevir. Experimental Irinotecan The serum concentration of Irinotecan can be increased when it is combined with Boceprevir. Approved, Investigational Isavuconazole The serum concentration of Isavuconazole can be increased when it is combined with Boceprevir. Approved, Investigational Isavuconazonium The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Boceprevir. Approved, Investigational Isoflurophate The serum concentration of Isoflurophate can be decreased when it is combined with Boceprevir. Approved, Investigational, Withdrawn Isosorbide Dinitrate The metabolism of Isosorbide Dinitrate can be decreased when combined with Boceprevir. Approved, Investigational Isosorbide Mononitrate The metabolism of Isosorbide Mononitrate can be decreased when combined with Boceprevir. Approved Isradipine The metabolism of Isradipine can be decreased when combined with Boceprevir. Approved, Investigational Istaroxime The serum concentration of Istaroxime can be increased when it is combined with Boceprevir. Investigational Itraconazole The serum concentration of Boceprevir can be increased when it is combined with Itraconazole. Approved, Investigational Ivabradine The serum concentration of Ivabradine can be increased when it is combined with Boceprevir. Approved Ivacaftor The serum concentration of Ivacaftor can be increased when it is combined with Boceprevir. Approved Ivermectin The metabolism of Ivermectin can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Ixabepilone The serum concentration of Ixabepilone can be increased when it is combined with Boceprevir. Approved, Investigational Ixazomib The serum concentration of Ixazomib can be decreased when it is combined with Boceprevir. Approved, Investigational Ketamine The metabolism of Ketamine can be decreased when combined with Boceprevir. Approved, Vet Approved Ketazolam The metabolism of Ketazolam can be decreased when combined with Boceprevir. Approved Ketobemidone The metabolism of Ketobemidone can be decreased when combined with Boceprevir. Approved, Investigational Ketoconazole The serum concentration of Boceprevir can be increased when it is combined with Ketoconazole. Approved, Investigational Lacidipine The serum concentration of Lacidipine can be increased when it is combined with Boceprevir. Approved, Investigational Lacosamide The serum concentration of Lacosamide can be increased when it is combined with Boceprevir. Approved Lansoprazole The metabolism of Lansoprazole can be decreased when combined with Boceprevir. Approved, Investigational Lapatinib The serum concentration of Lapatinib can be increased when it is combined with Boceprevir. Approved, Investigational Laquinimod The metabolism of Laquinimod can be decreased when combined with Boceprevir. Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Boceprevir. Approved Lenvatinib The metabolism of Lenvatinib can be decreased when combined with Boceprevir. Approved, Investigational Lepirudin The serum concentration of Lepirudin can be decreased when it is combined with Boceprevir. Approved Lercanidipine The serum concentration of Lercanidipine can be increased when it is combined with Boceprevir. Approved, Investigational Letaxaban The serum concentration of Letaxaban can be decreased when it is combined with Boceprevir. Investigational Letrozole The metabolism of Letrozole can be decreased when combined with Boceprevir. Approved, Investigational Levobupivacaine The serum concentration of Levobupivacaine can be increased when it is combined with Boceprevir. Approved, Investigational Levocetirizine The metabolism of Levocetirizine can be decreased when combined with Boceprevir. Approved Levomethadyl Acetate The metabolism of Levomethadyl Acetate can be decreased when combined with Boceprevir. Approved, Investigational Levomilnacipran The serum concentration of Levomilnacipran can be increased when it is combined with Boceprevir. Approved, Investigational Levonorgestrel The serum concentration of Levonorgestrel can be increased when it is combined with Boceprevir. Approved, Investigational Levothyroxine The metabolism of Levothyroxine can be decreased when combined with Boceprevir. Approved Lidocaine The metabolism of Lidocaine can be decreased when combined with Boceprevir. Approved, Vet Approved Linagliptin The serum concentration of Linagliptin can be decreased when it is combined with Boceprevir. Approved Lisinopril The serum concentration of Lisinopril can be decreased when it is combined with Boceprevir. Approved, Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Boceprevir. Approved, Investigational Lofepramine The serum concentration of Lofepramine can be increased when it is combined with Boceprevir. Experimental Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Boceprevir. Approved, Investigational Loperamide The metabolism of Loperamide can be decreased when combined with Boceprevir. Approved Lopinavir The serum concentration of Lopinavir can be decreased when it is combined with Boceprevir. Approved Loratadine The metabolism of Loratadine can be decreased when combined with Boceprevir. Approved, Investigational Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Boceprevir. Approved Lorpiprazole The serum concentration of Boceprevir can be increased when it is combined with Lorpiprazole. Approved Losartan The metabolism of Losartan can be decreased when combined with Boceprevir. Approved Loteprednol The serum concentration of Loteprednol can be increased when it is combined with Boceprevir. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Boceprevir. Approved, Investigational Luliconazole The serum concentration of Boceprevir can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Boceprevir can be decreased when it is combined with Lumacaftor. Approved Lumefantrine The serum concentration of Lumefantrine can be increased when it is combined with Boceprevir. Approved Lurasidone The serum concentration of Lurasidone can be increased when it is combined with Boceprevir. Approved, Investigational Lynestrenol The serum concentration of Lynestrenol can be increased when it is combined with Boceprevir. Approved, Investigational Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Boceprevir. Illicit, Investigational, Withdrawn Macimorelin The metabolism of Macimorelin can be decreased when combined with Boceprevir. Approved, Investigational Macitentan The serum concentration of Macitentan can be increased when it is combined with Boceprevir. Approved Maraviroc The serum concentration of Maraviroc can be increased when it is combined with Boceprevir. Approved, Investigational ME-609 The serum concentration of ME-609 can be increased when it is combined with Boceprevir. Investigational Mebendazole The metabolism of Mebendazole can be decreased when combined with Boceprevir. Approved, Vet Approved Medroxyprogesterone acetate The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Boceprevir. Approved, Investigational Medrysone The serum concentration of Medrysone can be increased when it is combined with Boceprevir. Approved Mefloquine The metabolism of Mefloquine can be decreased when combined with Boceprevir. Approved, Investigational Melagatran The serum concentration of Melagatran can be decreased when it is combined with Boceprevir. Experimental Melengestrol The serum concentration of Melengestrol can be increased when it is combined with Boceprevir. Vet Approved Meloxicam The metabolism of Meloxicam can be decreased when combined with Boceprevir. Approved, Vet Approved Mestranol The serum concentration of Mestranol can be decreased when it is combined with Boceprevir. Approved Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Boceprevir. Experimental Methadone The serum concentration of Methadone can be increased when it is combined with Boceprevir. Approved Methallenestril The serum concentration of Methallenestril can be decreased when it is combined with Boceprevir. Experimental Methaqualone The metabolism of Methaqualone can be decreased when combined with Boceprevir. Illicit, Withdrawn Methoxsalen The metabolism of Methoxsalen can be decreased when combined with Boceprevir. Approved Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Methylergometrine The serum concentration of Methylergometrine can be increased when it is combined with Boceprevir. Approved Methylprednisolone The serum concentration of Methylprednisolone can be increased when it is combined with Boceprevir. Approved, Vet Approved Methyltestosterone The metabolism of Methyltestosterone can be decreased when combined with Boceprevir. Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Boceprevir. Approved Metronidazole The metabolism of Metronidazole can be decreased when combined with Boceprevir. Approved Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Boceprevir. Experimental Mexiletine The metabolism of Mexiletine can be decreased when combined with Boceprevir. Approved, Investigational Mianserin The metabolism of Mianserin can be decreased when combined with Boceprevir. Approved, Investigational Mibefradil The metabolism of Mibefradil can be decreased when combined with Boceprevir. Investigational, Withdrawn Miconazole The metabolism of Miconazole can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Midazolam The serum concentration of Midazolam can be increased when it is combined with Boceprevir. Approved, Illicit Midostaurin The metabolism of Midostaurin can be decreased when combined with Boceprevir. Approved, Investigational Mifepristone The serum concentration of Boceprevir can be increased when it is combined with Mifepristone. Approved, Investigational Mirabegron The metabolism of Mirabegron can be decreased when combined with Boceprevir. Approved Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Boceprevir. Approved Mitotane The serum concentration of Boceprevir can be decreased when it is combined with Mitotane. Approved Modafinil The metabolism of Modafinil can be decreased when combined with Boceprevir. Approved, Investigational Moexipril The serum concentration of Moexipril can be decreased when it is combined with Boceprevir. Approved Mometasone The serum concentration of Mometasone can be increased when it is combined with Boceprevir. Approved, Vet Approved Montelukast The metabolism of Montelukast can be decreased when combined with Boceprevir. Approved Morphine The metabolism of Morphine can be decreased when combined with Boceprevir. Approved, Investigational Mycophenolate mofetil The metabolism of Mycophenolate mofetil can be decreased when combined with Boceprevir. Approved, Investigational N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline The serum concentration of N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline can be decreased when it is combined with Boceprevir. Experimental Nafamostat The serum concentration of Nafamostat can be decreased when it is combined with Boceprevir. Approved, Investigational Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Boceprevir. Approved Naloxone The metabolism of Naloxone can be decreased when combined with Boceprevir. Approved, Vet Approved Nateglinide The metabolism of Nateglinide can be decreased when combined with Boceprevir. Approved, Investigational NCX 1022 The serum concentration of NCX 1022 can be increased when it is combined with Boceprevir. Investigational Nefazodone The serum concentration of Nefazodone can be increased when it is combined with Boceprevir. Approved, Withdrawn Nelfinavir The serum concentration of Nelfinavir can be decreased when it is combined with Boceprevir. Approved Neratinib The metabolism of Neratinib can be decreased when combined with Boceprevir. Approved, Investigational Netupitant The serum concentration of Boceprevir can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The serum concentration of Boceprevir can be decreased when it is combined with Nevirapine. Approved Nicardipine The metabolism of Nicardipine can be decreased when combined with Boceprevir. Approved, Investigational Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Boceprevir. Approved, Investigational Nicotine The metabolism of Nicotine can be decreased when combined with Boceprevir. Approved Nifedipine The metabolism of Nifedipine can be decreased when combined with Boceprevir. Approved Nilotinib The serum concentration of Nilotinib can be increased when it is combined with Boceprevir. Approved, Investigational Nilvadipine The metabolism of Nilvadipine can be decreased when combined with Boceprevir. Approved, Investigational Nimodipine The serum concentration of Nimodipine can be increased when it is combined with Boceprevir. Approved, Investigational Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Boceprevir. Approved Nisoldipine The serum concentration of Nisoldipine can be increased when it is combined with Boceprevir. Approved Nisoldipine The metabolism of Nisoldipine can be decreased when combined with Boceprevir. Approved Nitrazepam The metabolism of Nitrazepam can be decreased when combined with Boceprevir. Approved Nitrendipine The metabolism of Nitrendipine can be decreased when combined with Boceprevir. Approved, Investigational Nitroaspirin The serum concentration of Nitroaspirin can be decreased when it is combined with Boceprevir. Investigational Norelgestromin The serum concentration of Norelgestromin can be increased when it is combined with Boceprevir. Approved, Investigational Norethisterone The metabolism of Norethisterone can be decreased when combined with Boceprevir. Approved Norgestimate The serum concentration of Norgestimate can be increased when it is combined with Boceprevir. Approved, Investigational Norgestrel The serum concentration of Norgestrel can be increased when it is combined with Boceprevir. Approved Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Boceprevir. Approved Odanacatib The metabolism of Odanacatib can be decreased when combined with Boceprevir. Investigational Olaparib The serum concentration of Olaparib can be increased when it is combined with Boceprevir. Approved Oleoyl-estrone The serum concentration of Oleoyl-estrone can be increased when it is combined with Boceprevir. Investigational Olopatadine The metabolism of Olopatadine can be decreased when combined with Boceprevir. Approved Omapatrilat The serum concentration of Omapatrilat can be decreased when it is combined with Boceprevir. Investigational Omeprazole The metabolism of Omeprazole can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Ondansetron The metabolism of Ondansetron can be decreased when combined with Boceprevir. Approved Opipramol The serum concentration of Opipramol can be increased when it is combined with Boceprevir. Investigational Opium The metabolism of Opium can be decreased when combined with Boceprevir. Approved, Illicit Orphenadrine The metabolism of Orphenadrine can be decreased when combined with Boceprevir. Approved Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Boceprevir. Approved Ospemifene The serum concentration of Ospemifene can be increased when it is combined with Boceprevir. Approved, Investigational Otamixaban The serum concentration of Otamixaban can be decreased when it is combined with Boceprevir. Investigational Oxazepam The metabolism of Oxazepam can be decreased when combined with Boceprevir. Approved Oxybutynin The serum concentration of Oxybutynin can be increased when it is combined with Boceprevir. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Boceprevir is combined with Oxycodone. Approved, Illicit, Investigational Oxymorphone The metabolism of Oxymorphone can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Boceprevir. Approved, Vet Approved Palbociclib The serum concentration of Palbociclib can be increased when it is combined with Boceprevir. Approved, Investigational Palonosetron The metabolism of Palonosetron can be decreased when combined with Boceprevir. Approved, Investigational Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Boceprevir. Approved, Investigational Pantoprazole The metabolism of Pantoprazole can be decreased when combined with Boceprevir. Approved Paramethadione The metabolism of Paramethadione can be decreased when combined with Boceprevir. Approved Paramethasone The metabolism of Paramethasone can be decreased when combined with Boceprevir. Approved Parecoxib The serum concentration of Parecoxib can be increased when it is combined with Boceprevir. Approved Paricalcitol The serum concentration of Paricalcitol can be increased when it is combined with Boceprevir. Approved, Investigational Paritaprevir The metabolism of Paritaprevir can be decreased when combined with Boceprevir. Approved, Investigational Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Boceprevir. Approved Pentamidine The metabolism of Pentamidine can be decreased when combined with Boceprevir. Approved, Investigational Pentobarbital The serum concentration of Boceprevir can be decreased when it is combined with Pentobarbital. Approved, Investigational, Vet Approved Perampanel The metabolism of Perampanel can be decreased when combined with Boceprevir. Approved Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Boceprevir. Approved, Investigational, Vet Approved, Withdrawn Perhexiline The metabolism of Perhexiline can be decreased when combined with Boceprevir. Approved, Investigational Perindopril The serum concentration of Perindopril can be decreased when it is combined with Boceprevir. Approved Permethrin The metabolism of Permethrin can be decreased when combined with Boceprevir. Approved, Investigational Perospirone The metabolism of Perospirone can be decreased when combined with Boceprevir. Approved Perphenazine The metabolism of Perphenazine can be decreased when combined with Boceprevir. Approved Pethidine The risk or severity of adverse effects can be increased when Boceprevir is combined with Pethidine. Approved Phenacetin The metabolism of Phenacetin can be decreased when combined with Boceprevir. Withdrawn Phenobarbital The serum concentration of Boceprevir can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenoxybenzamine The metabolism of Phenoxybenzamine can be decreased when combined with Boceprevir. Approved Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Boceprevir. Approved, Investigational Phenytoin The serum concentration of Boceprevir can be decreased when it is combined with Phenytoin. Approved, Vet Approved Phosphoramidon The serum concentration of Phosphoramidon can be decreased when it is combined with Boceprevir. Experimental Pilocarpine The metabolism of Pilocarpine can be decreased when combined with Boceprevir. Approved, Investigational Pimecrolimus The metabolism of Pimecrolimus can be decreased when combined with Boceprevir. Approved, Investigational Pimozide The serum concentration of Pimozide can be increased when it is combined with Boceprevir. Approved Pinacidil The metabolism of Pinacidil can be decreased when combined with Boceprevir. Approved Pioglitazone The metabolism of Pioglitazone can be decreased when combined with Boceprevir. Approved, Investigational Piperaquine The metabolism of Piperaquine can be decreased when combined with Boceprevir. Approved, Investigational Pipotiazine The metabolism of Pipotiazine can be decreased when combined with Boceprevir. Approved, Investigational Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Boceprevir. Approved Pitolisant The serum concentration of Boceprevir can be decreased when it is combined with Pitolisant. Approved, Investigational Podofilox The metabolism of Podofilox can be decreased when combined with Boceprevir. Approved Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Boceprevir. Approved Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Boceprevir. Approved, Investigational Posaconazole The serum concentration of Boceprevir can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Pranlukast The serum concentration of Pranlukast can be increased when it is combined with Boceprevir. Approved, Investigational Prasterone The metabolism of Prasterone can be decreased when combined with Boceprevir. Approved, Investigational, Nutraceutical Prasterone sulfate The serum concentration of Prasterone sulfate can be increased when it is combined with Boceprevir. Investigational Prasugrel The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Boceprevir resulting in a loss in efficacy. Approved Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Boceprevir. Approved Prazepam The metabolism of Prazepam can be decreased when combined with Boceprevir. Approved, Illicit Praziquantel The metabolism of Praziquantel can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Prednicarbate The serum concentration of Prednicarbate can be increased when it is combined with Boceprevir. Approved, Investigational Prednisolone The serum concentration of Prednisolone can be increased when it is combined with Boceprevir. Approved, Vet Approved Prednisone The serum concentration of Prednisone can be increased when it is combined with Boceprevir. Approved, Vet Approved Pregnenolone The serum concentration of Pregnenolone can be increased when it is combined with Boceprevir. Approved, Experimental, Investigational Primaquine The metabolism of Primaquine can be decreased when combined with Boceprevir. Approved Primidone The serum concentration of Boceprevir can be decreased when it is combined with Primidone. Approved, Vet Approved Prinomastat The serum concentration of Prinomastat can be decreased when it is combined with Boceprevir. Investigational Prochlorperazine The metabolism of Prochlorperazine can be decreased when combined with Boceprevir. Approved, Vet Approved Progesterone The metabolism of Progesterone can be decreased when combined with Boceprevir. Approved, Vet Approved Proguanil The metabolism of Proguanil can be decreased when combined with Boceprevir. Approved Promazine The metabolism of Promazine can be decreased when combined with Boceprevir. Approved, Vet Approved Propafenone The serum concentration of Propafenone can be increased when it is combined with Boceprevir. Approved Propofol The metabolism of Propofol can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Propoxyphene napsylate The metabolism of Propoxyphene napsylate can be decreased when combined with Boceprevir. Approved Propranolol The metabolism of Propranolol can be decreased when combined with Boceprevir. Approved, Investigational Protriptyline The serum concentration of Protriptyline can be increased when it is combined with Boceprevir. Approved Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Boceprevir. Approved Pyrazinamide The metabolism of Pyrazinamide can be decreased when combined with Boceprevir. Approved, Investigational Quazepam The metabolism of Quazepam can be decreased when combined with Boceprevir. Approved, Illicit Quetiapine The serum concentration of Quetiapine can be increased when it is combined with Boceprevir. Approved Quinacrine The metabolism of Quinacrine can be decreased when combined with Boceprevir. Approved, Investigational Quinapril The serum concentration of Quinapril can be decreased when it is combined with Boceprevir. Approved, Investigational Quinidine The serum concentration of Quinidine can be increased when it is combined with Boceprevir. Approved, Investigational Quinine The metabolism of Quinine can be decreased when combined with Boceprevir. Approved Rabeprazole The metabolism of Rabeprazole can be decreased when combined with Boceprevir. Approved, Investigational Racecadotril The serum concentration of Racecadotril can be decreased when it is combined with Boceprevir. Investigational Raloxifene The metabolism of Raloxifene can be decreased when combined with Boceprevir. Approved, Investigational Ramelteon The serum concentration of Ramelteon can be increased when it is combined with Boceprevir. Approved, Investigational Ramipril The serum concentration of Ramipril can be decreased when it is combined with Boceprevir. Approved Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Boceprevir. Approved, Investigational Reboxetine The metabolism of Reboxetine can be decreased when combined with Boceprevir. Approved, Investigational Regorafenib The metabolism of Regorafenib can be decreased when combined with Boceprevir. Approved Remikiren The serum concentration of Remikiren can be decreased when it is combined with Boceprevir. Approved Repaglinide The serum concentration of Repaglinide can be increased when it is combined with Boceprevir. Approved, Investigational Retapamulin The serum concentration of Retapamulin can be increased when it is combined with Boceprevir. Approved Ribociclib The serum concentration of Ribociclib can be increased when it is combined with Boceprevir. Approved, Investigational Rifabutin The serum concentration of Boceprevir can be decreased when it is combined with Rifabutin. Approved, Investigational Rifampicin The serum concentration of Boceprevir can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Boceprevir can be decreased when it is combined with Rifapentine. Approved, Investigational Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Boceprevir. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Boceprevir. Approved Rimexolone The serum concentration of Rimexolone can be increased when it is combined with Boceprevir. Approved Rimonabant The metabolism of Rimonabant can be decreased when combined with Boceprevir. Approved, Investigational Riociguat The serum concentration of Riociguat can be increased when it is combined with Boceprevir. Approved Risperidone The metabolism of Risperidone can be decreased when combined with Boceprevir. Approved, Investigational Ritonavir The serum concentration of Boceprevir can be decreased when it is combined with Ritonavir. Approved, Investigational Rivaroxaban The serum concentration of Rivaroxaban can be decreased when it is combined with Boceprevir. Approved Rofecoxib The metabolism of Rofecoxib can be decreased when combined with Boceprevir. Approved, Investigational, Withdrawn Rolapitant The metabolism of Rolapitant can be decreased when combined with Boceprevir. Approved, Investigational Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Boceprevir. Approved, Investigational Ropinirole The metabolism of Ropinirole can be decreased when combined with Boceprevir. Approved, Investigational Ropivacaine The metabolism of Ropivacaine can be decreased when combined with Boceprevir. Approved Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Boceprevir. Approved Rotigotine The metabolism of Rotigotine can be decreased when combined with Boceprevir. Approved Roxithromycin The metabolism of Roxithromycin can be decreased when combined with Boceprevir. Approved, Investigational, Withdrawn Rucaparib The metabolism of Rucaparib can be decreased when combined with Boceprevir. Approved, Investigational Rupatadine The metabolism of Rupatadine can be decreased when combined with Boceprevir. Approved Ruxolitinib The serum concentration of Ruxolitinib can be increased when it is combined with Boceprevir. Approved S-3304 The serum concentration of S-3304 can be decreased when it is combined with Boceprevir. Investigational Safinamide The metabolism of Safinamide can be decreased when combined with Boceprevir. Approved, Investigational Salmeterol The serum concentration of Salmeterol can be increased when it is combined with Boceprevir. Approved Salmeterol The metabolism of Salmeterol can be decreased when combined with Boceprevir. Approved Saquinavir The serum concentration of Saquinavir can be decreased when it is combined with Boceprevir. Approved, Investigational Sarilumab The therapeutic efficacy of Boceprevir can be decreased when used in combination with Sarilumab. Approved, Investigational Saxagliptin The serum concentration of Saxagliptin can be decreased when it is combined with Boceprevir. Approved Selegiline The metabolism of Selegiline can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Selexipag The metabolism of Selexipag can be decreased when combined with Boceprevir. Approved Seratrodast The metabolism of Seratrodast can be decreased when combined with Boceprevir. Approved Sertindole The metabolism of Sertindole can be decreased when combined with Boceprevir. Approved, Investigational, Withdrawn Sertraline The metabolism of Sertraline can be decreased when combined with Boceprevir. Approved Sevoflurane The metabolism of Sevoflurane can be decreased when combined with Boceprevir. Approved, Vet Approved Sibutramine The metabolism of Sibutramine can be decreased when combined with Boceprevir. Approved, Illicit, Investigational, Withdrawn Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Boceprevir. Approved, Investigational Silodosin The serum concentration of Silodosin can be increased when it is combined with Boceprevir. Approved Siltuximab The serum concentration of Boceprevir can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Simeprevir can be increased when it is combined with Boceprevir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Boceprevir. Approved Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Boceprevir. Approved, Investigational Sitagliptin The serum concentration of Sitagliptin can be decreased when it is combined with Boceprevir. Approved, Investigational Sivelestat The serum concentration of Sivelestat can be decreased when it is combined with Boceprevir. Investigational Solifenacin The metabolism of Solifenacin can be decreased when combined with Boceprevir. Approved Sonidegib The serum concentration of Sonidegib can be increased when it is combined with Boceprevir. Approved, Investigational Sorafenib The serum concentration of Sorafenib can be increased when it is combined with Boceprevir. Approved, Investigational Spiramycin The metabolism of Spiramycin can be decreased when combined with Boceprevir. Approved Spirapril The serum concentration of Spirapril can be decreased when it is combined with Boceprevir. Approved St. John's Wort The serum concentration of Boceprevir can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Boceprevir can be increased when it is combined with Stiripentol. Approved Sufentanil The metabolism of Sufentanil can be decreased when combined with Boceprevir. Approved, Investigational Sulfadiazine The metabolism of Sulfadiazine can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Sulfamethoxazole The metabolism of Sulfamethoxazole can be decreased when combined with Boceprevir. Approved Sulfinpyrazone The metabolism of Sulfinpyrazone can be decreased when combined with Boceprevir. Approved Sulfisoxazole The metabolism of Boceprevir can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sunitinib The metabolism of Sunitinib can be decreased when combined with Boceprevir. Approved, Investigational Suvorexant The serum concentration of Suvorexant can be increased when it is combined with Boceprevir. Approved, Investigational Synthetic Conjugated Estrogens, A The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Boceprevir. Approved Synthetic Conjugated Estrogens, B The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Boceprevir. Approved Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Boceprevir. Approved, Investigational Tadalafil The serum concentration of Tadalafil can be increased when it is combined with Boceprevir. Approved, Investigational Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Boceprevir. Approved Tamsulosin The serum concentration of Tamsulosin can be increased when it is combined with Boceprevir. Approved, Investigational Tasimelteon The serum concentration of Tasimelteon can be increased when it is combined with Boceprevir. Approved, Investigational Tasosartan The metabolism of Tasosartan can be decreased when combined with Boceprevir. Approved Taurochenodeoxycholic acid The metabolism of Taurochenodeoxycholic acid can be decreased when combined with Boceprevir. Experimental Telaprevir The serum concentration of Telaprevir can be decreased when it is combined with Boceprevir. Approved, Withdrawn Telithromycin The metabolism of Boceprevir can be decreased when combined with Telithromycin. Approved Temazepam The metabolism of Temazepam can be decreased when combined with Boceprevir. Approved, Investigational Temocapril The serum concentration of Temocapril can be decreased when it is combined with Boceprevir. Experimental, Investigational Temsirolimus The risk or severity of adverse effects can be increased when Boceprevir is combined with Temsirolimus. Approved Teniposide The metabolism of Teniposide can be decreased when combined with Boceprevir. Approved Terbinafine The metabolism of Terbinafine can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Terfenadine The serum concentration of Terfenadine can be increased when it is combined with Boceprevir. Approved, Withdrawn Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Boceprevir. Experimental Tesmilifene The metabolism of Tesmilifene can be decreased when combined with Boceprevir. Investigational Testosterone The metabolism of Testosterone can be decreased when combined with Boceprevir. Approved, Investigational Testosterone cypionate The metabolism of Testosterone cypionate can be decreased when combined with Boceprevir. Approved Testosterone enanthate The metabolism of Testosterone enanthate can be decreased when combined with Boceprevir. Approved Testosterone propionate The metabolism of Testosterone propionate can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate The metabolism of Testosterone undecanoate can be decreased when combined with Boceprevir. Approved, Investigational Tetracycline The metabolism of Tetracycline can be decreased when combined with Boceprevir. Approved, Vet Approved Tezacaftor The metabolism of Tezacaftor can be decreased when combined with Boceprevir. Approved, Investigational Theophylline The metabolism of Theophylline can be decreased when combined with Boceprevir. Approved Thiorphan The serum concentration of Thiorphan can be decreased when it is combined with Boceprevir. Experimental Thiotepa The metabolism of Thiotepa can be decreased when combined with Boceprevir. Approved, Investigational Tiagabine The metabolism of Tiagabine can be decreased when combined with Boceprevir. Approved, Investigational Tianeptine The serum concentration of Tianeptine can be increased when it is combined with Boceprevir. Approved, Investigational Ticagrelor The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Boceprevir resulting in a loss in efficacy. Approved Ticlopidine The metabolism of Ticlopidine can be decreased when combined with Boceprevir. Approved Tinidazole The metabolism of Tinidazole can be decreased when combined with Boceprevir. Approved, Investigational Tiotropium The metabolism of Tiotropium can be decreased when combined with Boceprevir. Approved Tipranavir The serum concentration of Boceprevir can be decreased when it is combined with Tipranavir. Approved, Investigational Tixocortol The serum concentration of Tixocortol can be increased when it is combined with Boceprevir. Approved, Withdrawn Tocilizumab The serum concentration of Boceprevir can be decreased when it is combined with Tocilizumab. Approved Tocopherol The metabolism of Tocopherol can be decreased when combined with Boceprevir. Approved, Investigational Tofacitinib The serum concentration of Tofacitinib can be increased when it is combined with Boceprevir. Approved, Investigational Tolterodine The serum concentration of Tolterodine can be increased when it is combined with Boceprevir. Approved, Investigational Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Boceprevir. Approved Topotecan The serum concentration of Topotecan can be increased when it is combined with Boceprevir. Approved, Investigational Toremifene The risk or severity of adverse effects can be increased when Boceprevir is combined with Toremifene. Approved, Investigational Trabectedin The serum concentration of Trabectedin can be increased when it is combined with Boceprevir. Approved, Investigational Tramadol The serum concentration of Tramadol can be increased when it is combined with Boceprevir. Approved, Investigational Trandolapril The serum concentration of Trandolapril can be decreased when it is combined with Boceprevir. Approved Trastuzumab emtansine The serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Boceprevir. Approved, Investigational Trazodone The serum concentration of Trazodone can be increased when it is combined with Boceprevir. Approved, Investigational Tretinoin The metabolism of Tretinoin can be decreased when combined with Boceprevir. Approved, Investigational, Nutraceutical Triamcinolone The metabolism of Triamcinolone can be decreased when combined with Boceprevir. Approved, Vet Approved Triazolam The serum concentration of Triazolam can be increased when it is combined with Boceprevir. Approved, Investigational Trimethadione The metabolism of Trimethadione can be decreased when combined with Boceprevir. Approved Trimethoprim The metabolism of Trimethoprim can be decreased when combined with Boceprevir. Approved, Vet Approved Trimipramine The metabolism of Trimipramine can be decreased when combined with Boceprevir. Approved Troglitazone The metabolism of Troglitazone can be decreased when combined with Boceprevir. Investigational, Withdrawn Troleandomycin The metabolism of Troleandomycin can be decreased when combined with Boceprevir. Approved Ubenimex The serum concentration of Ubenimex can be decreased when it is combined with Boceprevir. Experimental, Investigational Udenafil The metabolism of Udenafil can be decreased when combined with Boceprevir. Approved, Investigational Ulinastatin The serum concentration of Ulinastatin can be decreased when it is combined with Boceprevir. Investigational Ulipristal The serum concentration of Ulipristal can be increased when it is combined with Boceprevir. Approved Ulobetasol The serum concentration of Ulobetasol can be increased when it is combined with Boceprevir. Approved Valbenazine The metabolism of Valbenazine can be decreased when combined with Boceprevir. Approved, Investigational Valdecoxib The metabolism of Valdecoxib can be decreased when combined with Boceprevir. Approved, Investigational, Withdrawn Valproic Acid The serum concentration of Valproic Acid can be decreased when it is combined with Boceprevir. Approved, Investigational Vandetanib The metabolism of Vandetanib can be decreased when combined with Boceprevir. Approved Vanoxerine The metabolism of Vanoxerine can be decreased when combined with Boceprevir. Investigational Vardenafil The serum concentration of Vardenafil can be increased when it is combined with Boceprevir. Approved Velpatasvir The metabolism of Velpatasvir can be decreased when combined with Boceprevir. Approved, Investigational Vemurafenib The serum concentration of Boceprevir can be decreased when it is combined with Vemurafenib. Approved Venetoclax The metabolism of Venetoclax can be decreased when combined with Boceprevir. Approved, Investigational Venlafaxine The metabolism of Venlafaxine can be decreased when combined with Boceprevir. Approved Verapamil The metabolism of Verapamil can be decreased when combined with Boceprevir. Approved Vicriviroc The metabolism of Vicriviroc can be decreased when combined with Boceprevir. Investigational Vilanterol The metabolism of Vilanterol can be decreased when combined with Boceprevir. Approved Vilazodone The serum concentration of Vilazodone can be increased when it is combined with Boceprevir. Approved Vildagliptin The serum concentration of Vildagliptin can be decreased when it is combined with Boceprevir. Approved, Investigational Vinblastine The metabolism of Vinblastine can be decreased when combined with Boceprevir. Approved Vincristine The serum concentration of Vincristine can be increased when it is combined with Boceprevir. Approved, Investigational Vincristine The metabolism of Vincristine can be decreased when combined with Boceprevir. Approved, Investigational Vindesine The serum concentration of Vindesine can be increased when it is combined with Boceprevir. Approved, Investigational Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Boceprevir. Approved, Investigational Vismodegib The metabolism of Vismodegib can be decreased when combined with Boceprevir. Approved, Investigational Vorapaxar The serum concentration of Vorapaxar can be increased when it is combined with Boceprevir. Approved Voriconazole The serum concentration of Voriconazole can be increased when it is combined with Boceprevir. Approved, Investigational Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Boceprevir. Approved, Investigational Voxilaprevir The metabolism of Voxilaprevir can be decreased when combined with Boceprevir. Approved, Investigational Warfarin The serum concentration of Warfarin can be decreased when it is combined with Boceprevir. Approved Ximelagatran The serum concentration of Ximelagatran can be decreased when it is combined with Boceprevir. Approved, Investigational, Withdrawn Yohimbine The metabolism of Yohimbine can be decreased when combined with Boceprevir. Approved, Investigational, Vet Approved Z-Val-Ala-Asp fluoromethyl ketone The serum concentration of Z-Val-Ala-Asp fluoromethyl ketone can be decreased when it is combined with Boceprevir. Experimental Zafirlukast The metabolism of Zafirlukast can be decreased when combined with Boceprevir. Approved, Investigational Zalcitabine The metabolism of Zalcitabine can be decreased when combined with Boceprevir. Approved, Investigational Zaleplon The metabolism of Zaleplon can be decreased when combined with Boceprevir. Approved, Illicit, Investigational Zidovudine The serum concentration of Zidovudine can be decreased when it is combined with Boceprevir. Approved Zileuton The metabolism of Zileuton can be decreased when combined with Boceprevir. Approved, Investigational, Withdrawn Ziprasidone The metabolism of Ziprasidone can be decreased when combined with Boceprevir. Approved Zofenopril The serum concentration of Zofenopril can be decreased when it is combined with Boceprevir. Experimental Zolpidem The metabolism of Zolpidem can be decreased when combined with Boceprevir. Approved Zomepirac The metabolism of Zomepirac can be decreased when combined with Boceprevir. Withdrawn Zonisamide The metabolism of Zonisamide can be decreased when combined with Boceprevir. Approved, Investigational Zopiclone The serum concentration of Zopiclone can be increased when it is combined with Boceprevir. Approved Zotepine The metabolism of Zotepine can be decreased when combined with Boceprevir. Approved, Investigational, Withdrawn Zuclopenthixol The serum concentration of Zuclopenthixol can be increased when it is combined with Boceprevir. Approved, Investigational - Food Interactions
- Food increases the exposure of boceprevir by up to 65%. However, bioavailability is not affected and thus can be taken without regards to meals.
References
- Synthesis Reference
James Lalonde, Tao Li, Jack Liang, Benjamin Mijts, Roger Sheldon, George S.K. Wong, Aleksey Zaks, "Substantially Stereomerically Pure Fused Bicyclic Proline Compounds and Processes for Preparing Boceprevir." U.S. Patent US20120289709, issued November 15, 2012.
US20120289709- General References
- Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. [PubMed:23140245]
- Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O'Mara E, Kasserra C, Gupta S, Hughes EA: Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012 Sep 1;51(9):619-28. doi: 10.2165/11633440-000000000-00000. [PubMed:22799589]
- Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM: Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol. 2012 Apr;26(4):205-10. [PubMed:22506260]
- Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, Chase R, Gheyas F, Hart A, Hesk D, Ingravallo P, Jiang C, Kong R, Lu J, Pichardo J, Prongay A, Skelton A, Tong X, Venkatraman S, Xia E, Girijavallabhan V, Njoroge FG: SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother. 2006 Mar;50(3):1013-20. [PubMed:16495264]
- Bagaglio S, Uberti-Foppa C, Morsica G: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017 May 12. doi: 10.1007/s40265-017-0753-x. [PubMed:28497432]
- Myers RP, Shah H, Burak KW, Cooper C, Feld JJ: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13. [PubMed:25585348]
- American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017. [Link]
- External Links
- KEGG Drug
- D08876
- PubChem Compound
- 10324367
- PubChem Substance
- 175427127
- ChemSpider
- 8499830
- BindingDB
- 12311
- ChEBI
- 68621
- ChEMBL
- CHEMBL218394
- PharmGKB
- PA165948902
- HET
- HU5
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Boceprevir
- ATC Codes
- J05AE12 — Boceprevir
- FDA label
- Download (403 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Capsule Oral 200 mg Capsule Oral 200 mg/1 Capsule; powder, for solution Oral; Subcutaneous - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US7772178 No 2007-11-11 2027-11-11 US US8119602 No 2007-03-17 2027-03-17 US USRE43298 No 2002-02-22 2022-02-22 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0234 mg/mL ALOGPS logP 1.93 ALOGPS logP 1.78 ChemAxon logS -4.4 ALOGPS pKa (Strongest Acidic) 12.44 ChemAxon pKa (Strongest Basic) -0.91 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 150.7 Å2 ChemAxon Rotatable Bond Count 10 ChemAxon Refractivity 138.2 m3·mol-1 ChemAxon Polarizability 56.78 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.6781 Blood Brain Barrier - 0.8805 Caco-2 permeable - 0.6532 P-glycoprotein substrate Substrate 0.8394 P-glycoprotein inhibitor I Inhibitor 0.671 P-glycoprotein inhibitor II Inhibitor 0.6377 Renal organic cation transporter Non-inhibitor 0.8188 CYP450 2C9 substrate Non-substrate 0.7965 CYP450 2D6 substrate Non-substrate 0.7996 CYP450 3A4 substrate Substrate 0.621 CYP450 1A2 substrate Non-inhibitor 0.7987 CYP450 2C9 inhibitor Non-inhibitor 0.7265 CYP450 2D6 inhibitor Non-inhibitor 0.87 CYP450 2C19 inhibitor Non-inhibitor 0.6908 CYP450 3A4 inhibitor Non-inhibitor 0.9659 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8434 Ames test Non AMES toxic 0.662 Carcinogenicity Non-carcinogens 0.8555 Biodegradation Ready biodegradable 0.5913 Rat acute toxicity 2.6263 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9828 hERG inhibition (predictor II) Non-inhibitor 0.7092
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as hybrid peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta) linked to each other through a peptide bond.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Peptidomimetics
- Sub Class
- Hybrid peptides
- Direct Parent
- Hybrid peptides
- Alternative Parents
- Dipeptides / Valine and derivatives / N-carbamoyl-alpha amino acids and derivatives / Alpha amino acid amides / Piperidinecarboxamides / N-acylpiperidines / Pyrrolidinecarboxamides / N-acylpyrrolidines / Fatty amides / Tertiary carboxylic acid amides show 9 more
- Substituents
- Hybrid peptide / Alpha-dipeptide / N-carbamoyl-alpha-amino acid or derivatives / Valine or derivatives / Alpha-amino acid amide / Alpha-amino acid or derivatives / Piperidinecarboxamide / 2-piperidinecarboxamide / N-acyl-piperidine / Pyrrolidine carboxylic acid or derivatives show 25 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- ureas, tripeptide (CHEBI:68621)
Targets
- Kind
- Protein
- Organism
- Hepatitis C virus
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type peptidase activity
- Specific Function
- Not Available
- Gene Name
- NS3/4A
- Uniprot ID
- B0B3C9
- Uniprot Name
- Genome polyprotein
- Molecular Weight
- 72789.28 Da
References
- Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Ozen A, Soumana D, Newton A, Petropoulos CJ, Huang W, Schiffer CA: Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol. 2013 Jul 19;8(7):1469-78. doi: 10.1021/cb400100g. Epub 2013 May 1. [PubMed:23594083]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. [PubMed:23140245]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. [PubMed:23140245]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. [PubMed:23140245]
Drug created on May 11, 2013 22:45 / Updated on March 02, 2018 03:43